ArticleIJU case reports2026
Metastatic Testicular Cancer Complicated by Myelodysplastic Syndrome.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The coexistence of testicular cancer and hematopoietic disorders is rare, and reports on optimal treatment strategies are limited. Here, we present a case of metastatic testicular cancer associated with myelodysplastic syndrome. Case Presentation: A 24-year-old man with pancytopenia underwent right orchiectomy for a right scrotal mass. Histopathological examination revealed embryonal carcinoma. Subsequent imaging demonstrated para-aortic lymph node metastasis. Pancytopenia was diagnosed as myelodysplastic syndrome. The patient received chemotherapy with dose modifications and a prolonged treatment course, followed by retroperitoneal lymph node dissection; viable tumor cells were identified in the resected specimens. After adjuvant chemotherapy, allogenic hematopoietic stem cell transplantation was performed for myelodysplastic syndrome. The patient remained free of testicular cancer recurrence for 2 years post-surgery. Conclusion: This case suggests that durable disease control may be achievable in metastatic testicular cancer associated with myelodysplastic syndrome through carefully managed chemotherapy and surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.